Abstract

Efficient T-cell targeting, infiltration and activation within tumors is crucial for successful adoptive T-cell therapy. Intravital microscopy is a powerful tool for the visualization of T-cell behavior within tumors, as well as spatial and temporal heterogeneity in response to immunotherapy. Here we describe an experimental approach for intravital imaging of adoptive T-cell morphology, mobility and trafficking in a skin-flap tumor model, following immune modulation with immune checkpoint inhibitors (ICIs) targeting PD-L1 and CTLA-4. A syngeneic model of ovalbumin and mCherry-expressing amelanotic mouse melanoma was used in conjunction with adoptively transferred OT-1+ cytotoxic T-cells expressing GFP to image antigen-specific live T-cell behavior within the tumor microenvironment. Dynamic image analysis of T-cell motility showed distinct CD8+ T-cell migration patterns and morpho-dynamics within different tumor compartments in response to ICIs: this approach was used to cluster T-cell behavior into four groups based on velocity and meandering index. The results showed that most T-cells within the tumor periphery demonstrated Lévy-like trajectories, consistent with tumor cell searching strategies. T-cells adjacent to tumor cells had reduced velocity and appeared to probe the local environment, consistent with cell-cell interactions. An increased number of T-cells were detected following treatment, traveling at lower mean velocities than controls, and demonstrating reduced displacement consistent with target engagement. Histogram-based analysis of immunofluorescent images from harvested tumors showed that in the ICI-treated mice there was a higher density of CD31+ vessels compared to untreated controls and a greater infiltration of T-cells towards the tumor core, consistent with increased cellular trafficking post-treatment.

Highlights

  • Adoptive T-cell therapy (ATC) is emerging as a promising approach for the treatment of solid cancers [1, 2]

  • The line was generated via the transfection of B16 parental cells with a vector containing mCherry and chicken ovalbumin genes intercalated with two self-cleavable porcine teschovirus-1 2A (P2A) sequences

  • B78ChOva-mCherry is an amelanotic clone derived from the immunologically cold mouse B16 melanoma cell line. It is an ideal syngeneic melanoma model for intravital imaging and immunotherapy for the following reasons: the presence of the BRAFV600E mutation in B78 murine melanoma is reflective of ∼50% of human malignant melanomas which have activating BRAF mutations; up to 20% of human melanoma are amelanotic or partially pigmented, and have poorer prognosis than pigmented tumors [35]

Read more

Summary

Introduction

Adoptive T-cell therapy (ATC) is emerging as a promising approach for the treatment of solid cancers [1, 2]. ATC presents significant challenges for routine clinical use due to variable patient response to therapy and the requirement for a high specificity to tumor-associated antigens [4, 5]. T-cell trafficking and infiltration into solid tumors is limited by physical barriers such as the stromal network and extracellular matrix surrounding the tumor cells. Regional delivery of T-cells via intratumoral injection has been proposed as a more targeted method to overcome these physical barriers, but remains technically challenging as not all tumors are accessible and it is difficult to reproducibly distribute the injected cells within the tumor [7, 8]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.